Harnessing NSG Mouse Models for The Development of An Allogeneic Gamma Delta CAR T Cell Therapy Platform
Time: 11:45 am
day: Conference Day One - Track 2 - AM
Details:
- The rationale for using allogeneic gamma delta CAR T cells for cancer therapy and how they are different from alpha betta CAR T cells
- Addressing the challenges and considerations in developing preclinical models for assessing activity and safety of this unique cell therapy product
- Showcasing a case study illustrating the successful transition of a gamma delta T cell program from NSG mouse models to clinical trials
